Nidan Laboratories and Healthcare (NSE:NIDAN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nidan Laboratories and Healthcare EBITDA Margin % Related Terms
Nidan Laboratories and Healthcare EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare EBITDA Margin % Chart
NSE:NIDAN vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Nidan Laboratories and Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nidan Laboratories and Healthcare EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Nidan Laboratories and Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nidan Laboratories and Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare (NSE:NIDAN) has a EBITDA Margin % of 25.77% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nidan Laboratories and Healthcare and its competitors.
Is Nidan Laboratories and Healthcare's EBITDA Margin % too high?
Nidan Laboratories and Healthcare's current EBITDA Margin % is 25.77%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Nidan Laboratories and Healthcare's value of 25.77% is 415.4% above this industry median. Overall, Nidan Laboratories and Healthcare has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Nidan Laboratories and Healthcare's EBITDA Margin % compare to TMO and DHR?
Nidan Laboratories and Healthcare's EBITDA Margin % of 25.77% can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBITDA Margin % is 5.00. Nidan Laboratories and Healthcare's value of 25.77% is 415.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nidan Laboratories and Healthcare's current EBITDA Margin % of 25.77% is 415.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nidan Laboratories and Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nidan Laboratories and Healthcare's current EBITDA Margin % is 25.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nidan Laboratories and Healthcare stock overvalued right now?
Nidan Laboratories and Healthcare (NSE:NIDAN) has a current EBITDA Margin % of 25.77%. The current EBITDA Margin % is 25.77% and 415.4% above the Medical Diagnostics & Research industry median of 5.00. Nidan Laboratories and Healthcare's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nidan Laboratories and Healthcare (NSE:NIDAN), the current EBITDA Margin % is 25.77% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nidan Laboratories and Healthcare Business Description
Nidan Laboratories and Healthcare Ltd offer diagnostic services including radiology, neurology, cardiology, dental as well as pathology services. The company provides pathology tests ranging from basic biochemistry and clinical pathology to cytogenetic and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-Rays, and ultrasounds to radiology tests including computerized tomography scans, magnetic resonance imaging scans.
67GF Score
Get the complete analysis for NSE:NIDAN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NIDAN has been successfully added to your 
